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First time in history…
“Never before in history has there been a situation where a bite from a 
mosquito could result in a devastating malformation.”
– Dr. Tom Frieden, CDC Director 
Fortune, April 13, 2016
What is Zika Virus?
 Single stranded RNA Virus
 Closely related to dengue, yellow fever, Japanese 
encephalitis, and West Nile viruses
 Primarily transmitted by two Aedes species mosquitoes
 Aedes aegypti and Aedes albopictus mosquitoes
 Additional modes of transmission





Aedes albopictus mosquito 
Where is Zika now?
As of July 14, 2016
50 countries and 
territories worldwide, 
including 41 countries 
and territories in the 
Americas, reporting 
active Zika virus 
transmission
Possibility of Local Mosquito-Borne 
Transmission in Continental US 
 Not able to predict how much Zika virus 
would spread in the continental US.
 Many areas in the United States have Aedes
mosquito.
 Recent outbreaks of chikungunya and 
dengue have been relatively small and 
limited to small area.
Maps have been updated from a variety of sources. These maps represent CDC's best estimate 
of the potential range of Aedes aegypti and Aedes albopictus in the United States. Maps are not 
meant to represent risk for spread of disease.
What are the symptoms?





• Conjunctivitis (red eyes)
 Many people infected with Zika virus 
won’t have symptoms or will only have 
mild symptoms. 
Zika and Pregnancy
Zika Virus Infection in Pregnant Women
 Pregnant women can be infected
• Through a mosquito bite
• Through sex with an infected partner
 If infected around conception
• Zika might present risk to fetus
 If infected during pregnancy
• Zika can be passed to the fetus during 
pregnancy or around the time of birth
Zika Virus in Pregnancy
 Incidence of Zika virus infection in 
pregnant women is not known
 Infection can occur in any trimester
 No evidence of more severe disease 
compared with non-pregnant people
 No evidence of increased susceptibility
Centers for Disease Control and Prevention, CDC Health Advisory:  Recognizing, Managing, and Reporting Zika Virus Infections in Travelers Returning from Central America, South America, the Caribbean and Mexico, 
2016.
Besnard, M., et al., Evidence of Perinatal Transmission of Zika Virus, French Polynesia, December 2013 and February 2014. Euro Surveill, 2014. 19(14): p. 1-5.
Oliveira Melo, A., et al., Zika Virus Intrauterine Infection Causes Fetal Brain Abnormality and Microcephaly: Tip of the Iceberg? Ultrasound in Obstetrics & Gynecology, 2016. 47(1): p. 6-7.
CDC Lab Confirms Zika In Fetal Tissues





• Products of conception
Brain Abnormalities Associated with






 Brain atrophy and asymmetry
 Enlargement of posterior fossa
 Ventriculomegaly
 Restricted middle cerebral artery 
flow






Karwowski MP, Nelson JM, Staples JE, et al. Zika Virus Disease: A CDC Update for Pediatric Health Care Providers. Pediatrics. 2016;137(5):e20160621
Infants with Microcephaly* 
Note scattered intracranial 
calcifications
Note large ventricles 
and volume loss
Typical newborn head CT scan
CT scan images 
courtesy of 







Fetal Brain Disruption Sequence
 First described in 1984 but noted in earlier literature
 Brain destruction resulting in collapse of the fetal skull, microcephaly, scalp rugae
and neurologic impairment
 Photos and x-ray from 1990 series*; phenotype appears to be present in affected 
babies in Brazil
*Moore, et al. J Pediatr 1990;116:383-386.
Reviewing the evidence for causality
Potential Risk of Microcephaly 
 1% - 13% estimated risk of microcephaly due to Zika
virus infection in first trimester
• Modeling based on current outbreak in Bahia, Brazil
 Important to remember: 
• Data limited (infection rates unknown; microcephaly 
cases still being reported)
• Microcephaly difficult to detect prenatally
• Microcephaly only one of a range of possible adverse 
outcomes
Johansson MA, Mier-Y-Teran-Romero L, Reefhuis J, Gilboa SM, Hills SL. Zika and the Risk of Microcephaly. N Engl J Med. 2016 May 25 [Epub
ahead of print]. 
Adverse Outcomes and Zika Virus
 Linked to miscarriage and stillbirth
• Evidence insufficient to confirm Zika virus as cause
 A range of problems related to brain injury have been detected:








Karwowski MP, Nelson JM, Staples JE, et al. Zika Virus Disease: A CDC Update for Pediatric Health Care Providers. Pediatrics. 2016;137(5):e20160621
Many Questions Remain
 What is the full range of potential health 
problems that Zika virus infection may cause? 
 What is the level of risk from a Zika virus infection 
during pregnancy?
 When during pregnancy Zika virus infection poses 
the highest risk to the fetus?
 What are other factors (e.g., co-occurring 
infection, nutrition, symptomatic vs. 
asymptomatic) that might affect the risk for birth 
defects? 
What CDC is Doing to Learn More
Collecting data for action
What CDC is Doing to Share Information
 Providing updated clinical guidance 
 Sharing up-to-date information 
 Responding to your inquiries (24/7 hotline)
• Call the CDC Emergency Operations Center Watch Desk at 770-488-7100 and ask for the 
Zika Pregnancy Hotline or email ZikaMCH@cdc.gov
Tools for Healthcare Providers
www.cdc.gov/Zika
*Free materials available in English and Spanish
CDC Guidance: Pregnancy
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Updated Pregnancy Guidance 
 Updates to Guidance 
• Expand real-time reverse transcription–polymerase chain reaction (rRT-PCR) testing
• Emerging data indicate Zika virus RNA can be detected for prolonged periods in some pregnant 
women
• Increase the proportion of pregnant women with Zika virus infection who receive a definitive 
diagnosis
• Testing options vary according to type of possible exposure and timing relative to last 
possible exposure
 Possible Exposure
• Travel to or living in area with Zika virus 
• Sex without barrier protection, such as a condom, with a partner who has traveled to or 
lives in in an area with active transmission of Zika virus
23
Updated Guidance: Symptomatic Pregnant Women
 Symptomatic pregnant women 
• Evaluated <2 weeks after symptom onset 
• Should receive Zika virus rRT-PCR testing of serum and urine
• Evaluated 2–12 weeks after symptom onset
• Should first have a Zika virus immunoglobulin (IgM) test
• If positive or equivocal, serum and urine rRT-PCR should be performed
24
Updated Guidance: Asymptomatic Pregnant Women
 Who live in areas without active Zika virus transmission, evaluated <2 weeks after 
their last possible exposure 
• rRT-PCR testing should be performed 
• If the rtRT-PCR test is negative, a Zika IgM test should be performed 2–12 weeks after the 
exposure
 Who live in an area without active Zika virus transmission, evaluated 2–12 weeks 
after their last possible exposure 
• Should receive a Zika virus IgM antibody test
• If positive or equivocal, serum and urine rRT-PCR should be performed
 Who live in areas with active Zika virus transmission
• Should receive Zika virus IgM antibody testing as part of routine obstetric care during 





Assess for possible Zika virus exposure
Evaluate for signs and symptoms of Zika virus disease
• Symptomatic : <2 weeks after symptom onset, or
• Asymptomatic & NOTliving in area with active Zika : <2 weeks after possible exposure
• Symptomatic: Zika IgM and dengue IgM
• Asymptomatic & NOTliving in area with active Zika : 
Zika IgM 2–12 weeks after exposure 
Zika rRT-PCR on serum and urine
Positive Zika rRT-PCR on serum or urine:
Recent Zika virus infection
Negative Zika rRT-PCR on serum and urine
Zika IgM and dengue IgM negative: 
No recent Zika virus infection
Zika IgM or dengue IgM positive or equivocal 
Presumptive recent Zika or dengue or  flavivirus infection
A 
Plaque reduction neutralization test  (PRNT)
Zika virus PRNT ≥10 and dengue virus PRNT <10:
Recent Zika virus Infect ion
Zika virus PRNT <10:
No recent evidence of Zika virus infection
Zika virus PRNT ≥10 and dengue virus PRNT ≥10: 
Recent flavivirus infect ion, specific virus cannot be ident ified
• Symptomatic: 2–12 weeks after symptom onset, or
• Asymptomatic & NOTliving in area with active Zika : 2–12 weeks after possible exposure, or
• Asymptomatic & living in area with active Zika: 1st and 2nd trimester
Zika IgM and dengue IgM on serum
Zika IgM positive or equivocal 
and  any result on dengue IgM :
Presumptive recent Zika or 
flavivirus infection
Zika IgM and dengue 
IgM negative: 
No recent Zika virus 
infection
Reflex Zika rRT-PCR on serum and urine 
Positive Zika rRT-PCR on serum:
Recent Zika virus infection
Negative Zika rRT-PCR 
on serum
Dengue IgM positive or 




Assessing Exposure to Zika
 All pregnant women should be asked at each prenatal care visit if:
• They traveled to or live in an area with active Zika virus transmission 
• They had sex without barrier protection, such as a condom, with a partner 
who has traveled to or lives in an area with active Zika virus transmission
 Testing recommendations vary based on timing since onset of symptoms 
and/or last possible exposure to Zika virus 
Diagnostic Testing
 Through emergency use authorizations, CDC is working to expand 
laboratory diagnostic testing in states
 Healthcare providers should contact their state health department to 
facilitate diagnostic testing
CDC Recommendations: Prevention 
Traveling to Areas with Active Zika Transmission
 Pregnant women should not travel to 
areas with Zika 
 If a pregnant woman must travel, she should
• Talk with her healthcare provider before 
she goes
• Strictly follow steps to prevent 
mosquito bites during the trip
• Take steps to prevent sexual 
transmission
• Talk with her healthcare provider after 
she returns, even if she doesn’t feel sick 
http://wwwnc.cdc.gov/travel/page/zika-information
Women and Their Partners Thinking about Pregnancy
WOMEN MEN
Recent travel to an area with Zika or sex without a condom with an infected partner
Zika virus disease Wait at least 8 weeks after symptom onset
Wait at least 6 months after symptom 
onset
No Zika virus disease Wait at least 8 weeks after exposure Wait at least 8 weeks after exposure
Residence in an area with Zika 
Zika virus disease Wait at least 8 weeks after symptom onset
Wait at least 6 months after symptom 
onset
No Zika virus disease Talk with health care provider Talk with health care provider
To prevent sexual transmission of Zika Virus
Use barrier methods consistently and correctly or abstain from sex:
 Couples in which a woman is pregnant
• for the duration of the pregnancy.
 Couples who are not pregnant and are not planning to become pregnant
• If partner had confirmed Zika virus:
• Men for at least 6 months after onset of illness;
• Women for at least 8 weeks after onset of illness.
• If one partner traveled to or resides in area with active Zika virus 
transmission but did not develop symptoms: 
• for at least 8 weeks after departure
• Couples living in area of active Zika virus transmission
• Consider while active transmission persists
Clinical Tool
http://www.cdc.gov/zika/pdfs/preconception-counseling.pdf
What You Can Do
US Zika Pregnancy Registry 
 Purpose of registry: 
To monitor pregnancy and infant outcomes following Zika virus infection 
during pregnancy and to inform clinical guidance and public health 
response
 How it works: 
The registry is a supplemental surveillance effort coordinated by CDC and 
dependent on the voluntary collaboration of the state, tribal, local, and 
territorial health departments
US Zika Pregnancy Registry 
 Who is included?
Pregnant women with laboratory evidence of Zika virus infection and 
exposed infants born to these women; infants with laboratory evidence of 
congenital Zika virus infection and their mothers
 How can you support the registry? 
Spread the word about the US Zika Pregnancy Registry and assist with 
health department follow-up for pregnant women and infants who are 
part of the registry
More information about Zika
 More information is available on the U.S. Zika Pregnancy Registry website 
at Registry website.  To contact CDC Registry staff, call the CDC Emergency 
Operations Center watch desk at 770-488-7100 and ask for the Zika 
Pregnancy Hotline or email ZIKApregnancy@cdc.gov
 More information on caring for pregnant women, infants, or children with 
Zika virus infection is available at CDC's Zika website. 
www.cdc.gov/zika
For more information, contact CDC
1-800-CDC-INFO (232-4636)
TTY:  1-888-232-6348    www.cdc.gov
The findings and conclusions in this report are those of the authors and do not necessarily represent the 
official position of the Centers for Disease Control and Prevention.
Thanks to our many collaborators and partners!
For clinical questions, please contact
ZikaMCH@cdc.gov
For U.S. Zika Pregnancy Registry questions, please contact
ZikaPregnancy@cdc.gov
Before We End Today’s Webinar…
 Question and Answer Session
 Continuing Educat ion
 A link to the post-test and evaluation will appear on 
your screen as soon as today’s webinar concludes. 
 If you exit out of the webinar prior to taking the post-
test and evaluation, you can access these links in an 
email we will send to you following today’s webinar. 
THANK YOU
